Declaration of interests JR reports clinical research grants from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept Therapeutics, Corxel, Eli Lilly, Hanmi, Merck, Novo Nordisk, Pfizer, Regeneron, Regor, Roche, Sanofi, Structure Therapeutics, and Terns; serves or has served on scientific advisory boards and received honorarium or consulting fees from Amgen, Applied Therapeutics, Arrowhead, Biomea Fusion, Boehringer Ingelheim, Corcept Therapeutics, Eccogene, Eli Lilly, Hanmi, i2O Therapeutics, Novo Nordisk, Regeneron, Roche, Sanofi, Structure Therapeutics, and Terns; and has received honoraria for lectures from Eli Lilly, Novo Nordisk, and Sanofi. LKB has received consulting honoraria from Amgen, Bayer, Dexcom, Eli Lilly, Endogenex, Novo Nordisk, Pfizer, Sanofi, and Xeris. RG is an employee and shareholder at Novo Nordisk. FG reports research grants from Eli Lilly and Roche Diabetes Care; consulting fees from Eli Lilly and Novo Nordisk; support for attending meetings or travel from AstraZeneca, Boehringer Ingelheim, Eli Lilly, LifeScan, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi Aventis; participation on advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly, LifeScan, MedImmune, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi Aventis; unpaid leadership for the European Foundation for the Study of Diabetes and European Association for the Study of Diabetes, Societá Italiana di Endocrinologia, and Fo.Ri.SIE; and support for medical writing and statistical analysis from AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi Aventis. NBJ is an employee and shareholder at Novo Nordisk. KRK has received advisory or consulting fees support from Antag Therapeutics, Metsera, Novo Nordisk, Roche Pharmaceuticals, and vTv Therapeutics; research-related contracts (paid to the institution) from Bayer, Boehringer Ingelheim, Carmot, Diasome, Eli Lilly, GentiBio, Novo Nordisk, Rhythm Pharmaceuticals, Roche Pharmaceuticals, and vTv Therapeutics; and salary support through the National Institutes of Health (K12TR004416, U54DK118612, and R21AA031892). UKT is an employee and shareholder at Novo Nordisk. JBB has received salary support from clinical trial contracts to his employer by Corcept Therapeutics, Dexcom, GentiBio, Novo Nordisk, and Sparrow Pharmaceuticals; has received salary support from consulting contracts to his employer by Novo Nordisk; is a consultant with personal compensation from Aardvark Therapeutics, Altimmune, Alveus Therapeutics, Amgen, Antag, Aqua Medical, AstraZeneca, Boehringer Ingelheim, Corcept Therapeutics, Dexcom, Eli Lilly, embecta, General Medicines Inc, GentiBio, Kayothera, Metsera, MiniMed, Pfizer, Recordati, Roche, Sparrow Pharmaceuticals, Vertex, vTv Therapeutics, and Zealand; has stock or stock options in Aardvark Therapeutics, Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health; and has received salary support from grants from the National Institutes of Health, Breakthrough T1D, and PCORI. ABJ has received clinical trials funding from Abbott, Amgen, Argenx, AstraZeneca, Eli Lilly, Novo Nordisk, Roche, and Sanofi Aventis; has received speaking honorarium or advisory compensation from Abbott, AbbVie, Amgen, Antibody, AstraZeneca, Bausch Healthcare, Bayer, Boehringer Ingelheim, Celltrion, Dexcom, Diabetes Canada, Eli Lilly, embecta, GSK, HLS Therapeutics, Insulet, Janssen, Kailera, Medtronic, Merck, Moderna, Novartis, Novo Nordisk, Pendopharm, Pfizer, Roche, Sandoz, Takeda, and Ypsomed.
PubMed
